On the public citation graph
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
0 signed · 2545 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19990915)86:6<944::aid-cncr8>3.0.co;2-popenalex-snapshot
Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma
inferredcites →https://doi.org/10.1007/978-3-642-59655-1openalex-snapshot
Histological Typing of Endocrine Tumours
inferredcites →https://doi.org/10.1016/0014-2964(68)90066-2openalex-snapshot
Progress in treatment of cancer of uterine cervix
inferredcites →https://doi.org/10.1016/j.ccr.2005.09.005openalex-snapshot
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
inferredcites →https://doi.org/10.1016/j.ejca.2009.02.011openalex-snapshot
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
inferredcites →https://doi.org/10.1016/s1359-6349(06)70084-2openalex-snapshot
78 POSTER Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models
inferredcites →https://doi.org/10.1016/s1479-666x(08)80033-9openalex-snapshot
Interventional treatment of neuroendocrine liver metastases
inferredcites →https://doi.org/10.1016/s1535-6108(02)00031-4openalex-snapshot
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis
inferredcites →https://doi.org/10.1038/nrd2380openalex-snapshot
Molecular basis for sunitinib efficacy and future clinical development
inferredcites →https://doi.org/10.1053/j.semnuclmed.2006.01.001openalex-snapshot
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
inferredcites →https://doi.org/10.1056/nejm198011203032101openalex-snapshot
Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejm199202203260804openalex-snapshot
Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1009290openalex-snapshot
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
inferredcites →https://doi.org/10.1067/msy.2001.117377openalex-snapshot
Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors
inferredcites →https://doi.org/10.1080/02841860601048388openalex-snapshot
Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas
inferredcites →https://doi.org/10.1093/annonc/mdh216openalex-snapshot
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
inferredcites →https://doi.org/10.1093/annonc/mdn351openalex-snapshot
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
inferredcites →https://doi.org/10.1093/jnci/85.5.365openalex-snapshot
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1097/01.coc.0000135343.06038.ebopenalex-snapshot
Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors
inferredcites →https://doi.org/10.1097/01.mp.0000077416.68489.50openalex-snapshot
Liver Metastases Arising from Well-Differentiated Pancreatic Endocrine Neoplasms Demonstrate Increased VEGF-C Expression
inferredcites →https://doi.org/10.1111/j.1365-2036.2009.04174.xopenalex-snapshot
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
inferredcites →https://doi.org/10.1111/j.1477-2574.2009.00082.xopenalex-snapshot
A simplified prognostic system for resected pancreatic neuroendocrine neoplasms
inferredcites →https://doi.org/10.1159/000098012openalex-snapshot
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
inferredcites →https://doi.org/10.1196/annals.1294.025openalex-snapshot
Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center
inferredcites →https://doi.org/10.1200/jco.1992.10.12.1914openalex-snapshot
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.
inferredcites →https://doi.org/10.1200/jco.1998.16.1.139openalex-snapshot
Interpreting the significance of changes in health-related quality-of-life scores.
inferredcites →https://doi.org/10.1200/jco.2004.04.024openalex-snapshot
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
inferredcites →https://doi.org/10.1200/jco.2005.02.2194openalex-snapshot
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
inferredcites →https://doi.org/10.1200/jco.2005.07.093openalex-snapshot
A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer
inferredcites →https://doi.org/10.1200/jco.2005.08.066openalex-snapshot
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
inferredcites →https://doi.org/10.1200/jco.2007.15.9020openalex-snapshot
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
inferredcites →https://doi.org/10.1200/jco.2008.20.5476openalex-snapshot
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2009.22.8510openalex-snapshot
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
inferredcites →https://doi.org/10.1200/jco.2009.24.2669openalex-snapshot
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.4003openalex-snapshot
Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.
inferredcites →https://doi.org/10.2165/00002018-200932090-00003openalex-snapshot
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.2242900openalex-extracted
The Efficacy and Cost of Biological Targeted Agents in Oncology
inferred← citeshttps://doi.org/10.1001/2013.jamasurg.351openalex-snapshot
Complex Cystic Lesions in the Liver Causing Abdominal Pain
inferred← citeshttps://doi.org/10.1001/archsurg.147.1.98openalex-snapshot
Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy
inferred← citeshttps://doi.org/10.1001/archsurg.2012.1261openalex-snapshot
Lymph Nodes and Survival in Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1001/jamainternmed.2015.2829openalex-snapshot
The Strength of Association Between Surrogate End Points and Survival in Oncology
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.31744openalex-snapshot
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.0290openalex-snapshot
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1001/jamaoncol.2015.3077openalex-snapshot
Unexpected Cardiac Masses
inferred← citeshttps://doi.org/10.1001/jamaoncol.2017.0589openalex-snapshot
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.3035openalex-snapshot
Management of Liver Neuroendocrine Tumors in 2018
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.6720openalex-snapshot
Therapeutic Options for Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1001/jamaoncol.2022.0212openalex-snapshot
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1001/jamaoncol.2024.4330openalex-snapshot
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
inferred← citeshttps://doi.org/10.1001/jamaoto.2014.1570openalex-snapshot
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
inferred← citeshttps://doi.org/10.1002/14651858.cd013700.pub2openalex-snapshot
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis
inferred← citeshttps://doi.org/10.1002/9781118307816.ch43openalex-snapshot
Evidence of Medical and Radionuclide‐Targeted Treatment of Endocrine Tumors of the Pancreas
inferred← citeshttps://doi.org/10.1002/9781118423318.ch9openalex-snapshot
Gastrointestinal Endocrine Cancer
inferred← citeshttps://doi.org/10.1002/9781118441213.rtd0048openalex-snapshot
Reactive Inflammatory Erythemas
inferred← citeshttps://doi.org/10.1002/9781118464557.ch28openalex-snapshot
Uncommon Cancers of the Stomach
inferred← citeshttps://doi.org/10.1002/9781118464557.ch30openalex-snapshot
Uncommon Hepatobiliary Tumors
inferred← citeshttps://doi.org/10.1002/9781118464557.ch32openalex-snapshot
Unusual Tumors of the Colon, Rectum, And Anus
inferred← citeshttps://doi.org/10.1002/9781118464557.ch64openalex-snapshot
Uncommon Tumors of the Gastrointestinal Tract in Children
inferred← citeshttps://doi.org/10.1002/9781118468753.ch15openalex-snapshot
Cancer of the liver, biliary tract and pancreas
inferred← citeshttps://doi.org/10.1002/9781118512074.ch57openalex-snapshot
Zollinger–Ellison Syndrome
inferred← citeshttps://doi.org/10.1002/9781118512074.ch88openalex-snapshot
Neuroendocrine Tumors of the Pancreas
inferred← citeshttps://doi.org/10.1002/9781118592168.ch39openalex-snapshot
Gastroenteropancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1002/9781118592168.ch44openalex-snapshot
Cancer of Unknown Primary Site
inferred← citeshttps://doi.org/10.1002/9781118783344.ch24openalex-snapshot
Clinical Toxicity Profile of VEGF Inhibitors
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm007openalex-snapshot
Cancer Genomics and Evolution
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm007.pub2openalex-snapshot
Cancer Genomics and Evolution
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm083openalex-snapshot
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm083.pub2openalex-snapshot
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm124.pub2openalex-snapshot
Neoplasms of Unknown Primary Site
inferred← citeshttps://doi.org/10.1002/9781119188421.ch126openalex-snapshot
Pancreatic Neuroendocrine Tumors in Multiple Neoplasia Syndromes
inferred← citeshttps://doi.org/10.1002/9781119188421.ch128openalex-snapshot
Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas
inferred← citeshttps://doi.org/10.1002/9781119196235.ch27openalex-snapshot
Uncommon Cancers of the Stomach
inferred← citeshttps://doi.org/10.1002/9781119196235.ch31openalex-snapshot
Unusual Tumors of the Colon, Rectum, and Anus
inferred← citeshttps://doi.org/10.1002/9781119196235.ch74openalex-snapshot
Uncommon Tumors of the Gastrointestinal Tract in Children
inferred← citeshttps://doi.org/10.1002/9781119570097.ch76openalex-snapshot
Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1002/9781119709268.rook047openalex-snapshot
Reactive Inflammatory Erythemas
inferred← citeshttps://doi.org/10.1002/9781119756422.ch24openalex-snapshot
Neuroendocrine Neoplasms of the Digestive System
inferred← citeshttps://doi.org/10.1002/9781119876007.ch104openalex-snapshot
Pancreatic Neuroendocrine Tumors in Multiple Neoplasia Syndromes
inferred← citeshttps://doi.org/10.1002/9781119876007.ch106openalex-snapshot
Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas
inferred← citeshttps://doi.org/10.1002/adbi.201900236openalex-snapshot
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
inferred← citeshttps://doi.org/10.1002/advs.202506883openalex-snapshot
ACSS2/AATF Drives Soluble FasL‐Mediated CD8 + T Cell Apoptosis in Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1002/advs.202516733openalex-snapshot
Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2‐Epigenetic Circuit
inferred← citeshttps://doi.org/10.1002/ags3.12458openalex-snapshot
Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
inferred← citeshttps://doi.org/10.1002/ags3.70082openalex-snapshot
Indications for Surgical Resection in Patients With Neuroendocrine Tumor Liver Metastases: An Intensive Surgical Experience of a High‐Volume Center
inferred← citeshttps://doi.org/10.1002/bjs.9603openalex-snapshot
Outcome of surgery for pancreatic neuroendocrine neoplasms
inferred← citeshttps://doi.org/10.1002/cam4.1795openalex-snapshot
The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation‐wide cancer registry‐based study from Taiwan
inferred← citeshttps://doi.org/10.1002/cam4.70744openalex-snapshot
Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [ 177 Lu ]Lu‐ DOTA ‐ TATE : Ad Hoc Analysis of the Phase III NETTER ‐1 Trial
inferred← citeshttps://doi.org/10.1002/cam4.70798openalex-snapshot
Characterization of the Pancreatic Neuroendocrine Neoplasm Immune Microenvironment
inferred← citeshttps://doi.org/10.1002/cam4.71931openalex-snapshot
Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1002/cam4.742openalex-snapshot
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/ccr3.71764openalex-snapshot
Treatment of G1 Duodenal Neuroendocrine Tumors With Hepatic Metastasis: A Case Report
inferred← citeshttps://doi.org/10.1002/ccr3.8152openalex-snapshot
Transformation of pancreatic nonfunctioning neuroendocrine tumor into metastatic insulinoma: A rare case report
inferred← citeshttps://doi.org/10.1002/cmdc.201500467openalex-snapshot
Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor
inferred← citeshttps://doi.org/10.1002/cncr.26616openalex-snapshot
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y‐DOTA‐D‐Phe1‐Tyr3 octreotide
inferred← citeshttps://doi.org/10.1002/cncr.27675openalex-snapshot
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas
inferred← citeshttps://doi.org/10.1002/cncr.28142openalex-snapshot
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
inferred← citeshttps://doi.org/10.1002/cncr.28341openalex-snapshot
Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes
inferred← citeshttps://doi.org/10.1002/cncr.28653openalex-snapshot
Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis
inferred← citeshttps://doi.org/10.1002/cncr.28726openalex-snapshot
Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study
inferred← citeshttps://doi.org/10.1002/cncr.28743openalex-snapshot
Surgical management of noncolorectal cancer liver metastases
inferred← citeshttps://doi.org/10.1002/cncr.28760openalex-snapshot
Therapeutic strategies for neuroendocrine liver metastases
inferred← citeshttps://doi.org/10.1002/cncr.31192openalex-snapshot
Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases
inferred← citeshttps://doi.org/10.1002/cncr.32865openalex-snapshot
The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/cncr.32883openalex-snapshot
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study
inferred← citeshttps://doi.org/10.1002/cncr.33978openalex-snapshot
Management recommendations for pancreatic manifestations of von Hippel–Lindau disease
inferred← citeshttps://doi.org/10.1002/cncr.34479openalex-snapshot
Annual report to the nation on the status of cancer, part 1: National cancer statistics
inferred← citeshttps://doi.org/10.1002/cncr.35463openalex-snapshot
Update in the management of gastroenteropancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/cncr.35871openalex-snapshot
Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
inferred← citeshttps://doi.org/10.1002/cncr.70019openalex-snapshot
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study—TCOG T1214 study
inferred← citeshttps://doi.org/10.1002/cncy.22073openalex-snapshot
Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms
inferred← citeshttps://doi.org/10.1002/cnr2.1282openalex-snapshot
Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
inferred← citeshttps://doi.org/10.1002/cpt.3432openalex-snapshot
Diagnosis and Management of Parathyroid Carcinoma
inferred← citeshttps://doi.org/10.1002/ejoc.201403088openalex-snapshot
Synthesis and Cytotoxic Activity of Self‐Assembling Squalene Conjugates of 3‐[(Pyrrol‐2‐yl)methylidene]‐2,3‐dihydro‐1H‐indol‐2‐one Anticancer Agents
inferred← citeshttps://doi.org/10.1002/ijc.27543openalex-snapshot
Pancreatic neuroendocrine tumors: A comprehensive review
inferred← citeshttps://doi.org/10.1002/ijc.28544openalex-snapshot
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trials
inferred← citeshttps://doi.org/10.1002/ijc.28715openalex-snapshot
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials
inferred← citeshttps://doi.org/10.1002/ijc.31562openalex-snapshot
Therapeutic targeting of tumor‐associated macrophages in pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/ijc.34294openalex-snapshot
Special issue “The advance of solid tumor research in China”: Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/ijc.70053openalex-snapshot
Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)
inferred← citeshttps://doi.org/10.1002/jccs.201900466openalex-snapshot
The inhibition profiles of 4'‐acylpyrrole–5‐fluoroindolin‐2‐ones with a C‐3' side chain for VEGFR2, PDGFR‐β, and FGFR‐1 protein kinases
inferred← citeshttps://doi.org/10.1002/jcu.70142openalex-snapshot
Early Detection of Myocardial Dysfunction by Two‐Dimensional Speckle Tracking Echocardiography and Myocardial Work in Patients With Gastroenteropancreatic Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1002/jhbp.1101openalex-snapshot
Safety and response after peptide receptor radionuclide therapy with 177 Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
inferred← citeshttps://doi.org/10.1002/jhbp.210openalex-snapshot
Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/jhbp.225openalex-snapshot
The up‐to‐date review of epidemiological pancreatic neuroendocrine tumors in Japan
inferred← citeshttps://doi.org/10.1002/jhbp.257openalex-snapshot
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/jmri.24569openalex-snapshot
Towards new response criteria in neuroendocrine tumors: Which changes in MRI parameters are associated with longer progression‐free survival after radioembolization of liver metastases?
inferred← citeshttps://doi.org/10.1002/jps.23412openalex-snapshot
Physicochemical Characteristics of Sunitinib Malate and its Process-Related Impurities
inferred← citeshttps://doi.org/10.1002/jso.23462openalex-snapshot
Surgical management of non‐colorectal hepatic metastasis
inferred← citeshttps://doi.org/10.1002/jso.23973openalex-snapshot
Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables
inferred← citeshttps://doi.org/10.1002/jso.24338openalex-snapshot
Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy
inferred← citeshttps://doi.org/10.1002/jso.25146openalex-snapshot
Analysis of recurrence after the resection of pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1002/mc.23519openalex-snapshot
PDZ‐binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway
inferred← citeshttps://doi.org/10.1002/mco2.181openalex-snapshot
Small molecule inhibitors targeting the cancers
inferred← citeshttps://doi.org/10.1002/onco.13611openalex-snapshot
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide
inferred← citeshttps://doi.org/10.1002/onco.13669openalex-snapshot
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1002/onco.13885openalex-snapshot
Sunitinib and Evofosfamide ( TH -302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE -1408 Trial
inferred← citeshttps://doi.org/10.1002/onco.13923openalex-snapshot
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
inferred← citeshttps://doi.org/10.1002/path.4053openalex-snapshot
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
inferred← citeshttps://doi.org/10.1002/path.4506openalex-snapshot
Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1002/path.5135openalex-snapshot
Reduced expression of the RNA‐binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis
inferred← citeshttps://doi.org/10.1002/pbc.30961openalex-snapshot
Alpha‐emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor
inferred← citeshttps://doi.org/10.1002/pbc.31258openalex-snapshot
Childhood pancreatic neuroendocrine neoplasms: A national experience
inferred← citeshttps://doi.org/10.1002/tcr.202200152openalex-snapshot
Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy
inferred← citeshttps://doi.org/10.1002/ueg2.12710openalex-snapshot
Pancreatic Neuroendocrine Neoplasms: Classification and Novel Role of Endoscopic Ultrasound in Diagnosis and Treatment Personalization
inferred← citeshttps://doi.org/10.1002/vrc2.1058openalex-snapshot
Ectopic insulinoma in a bitch (Canis familiaris)
inferred← citeshttps://doi.org/10.1002/vro2.27openalex-snapshot
Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)
inferred← citeshttps://doi.org/10.1007/7355_2016_28openalex-snapshot
Inhibitors of Vascular Endothelial Growth Factor Receptor
inferred← citeshttps://doi.org/10.1007/7355_2020_100openalex-snapshot
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
inferred← citeshttps://doi.org/10.1007/978-1-4419-0751-6_33openalex-snapshot
Combination Therapy for Liver Metastases: Chemotherapy and Radiologic Interventions
inferred← citeshttps://doi.org/10.1007/978-1-4939-1423-4_24openalex-snapshot
Pancreatic Neuroendocrine Tumors (PNETs)
inferred← citeshttps://doi.org/10.1007/978-1-4939-1423-4_25openalex-snapshot
Multiple Endocrine Neoplasia (MEN) Syndromes
inferred← citeshttps://doi.org/10.1007/978-1-4939-1622-1_8openalex-snapshot
First-Generation Tyrosine Kinase Inhibitors: Clinical Results
inferred← citeshttps://doi.org/10.1007/978-1-4939-1798-3_12openalex-snapshot
Novel Targets for Future Medical Treatments
inferred← citeshttps://doi.org/10.1007/978-1-4939-1798-3_4openalex-snapshot
Zollinger–Ellison Syndrome: Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/978-1-4939-3426-3_25openalex-snapshot
Pathologic Angiogenesis in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-1-4939-3426-3_28openalex-snapshot
Targeted Therapies for Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1007/978-1-4939-6631-8_8-2openalex-snapshot
Sporadic Pancreatic Endocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-1-4939-7193-0_8openalex-snapshot
Sporadic Pancreatic Endocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-1-59745-458-2_11openalex-snapshot
Novel Cancer Therapies Targeting Angiogenesis
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_10openalex-snapshot
Clinical Management of Targeted Therapies in Neuroendocrine Tumours
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_11openalex-snapshot
Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_12openalex-snapshot
Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_13openalex-snapshot
New Anticancer Agents in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_14openalex-snapshot
Measuring the Relationship of Quality of Life and Health Status: Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_2openalex-snapshot
Profiling mTOR Pathway in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_3openalex-snapshot
Relevance of Angiogenesis in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_4openalex-snapshot
Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_5openalex-snapshot
Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?
inferred← citeshttps://doi.org/10.1007/978-2-8178-0430-9_9openalex-snapshot
Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0466-8_18openalex-snapshot
Antiangiogenic Drugs in Cancer Therapy: Effect on Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/978-2-8178-0492-7_10openalex-snapshot
Predictive Biomarkers of Response to mTOR Inhibitors
inferred← citeshttps://doi.org/10.1007/978-2-8178-0527-6_22openalex-snapshot
Traitement des tumeurs neuroendocrines digestives par les inhibiteurs de mTOR : les prémices d’un traitement personnalisé
inferred← citeshttps://doi.org/10.1007/978-3-030-16245-0_38openalex-snapshot
Clinical Approaches to the Management of Neuroendocrine Tumours
inferred← citeshttps://doi.org/10.1007/978-3-030-17494-1_4openalex-snapshot
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-18890-0_16openalex-snapshot
Gastroenteropancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-19632-5_20-1openalex-snapshot
MEN1 Bone Complications
inferred← citeshttps://doi.org/10.1007/978-3-030-22433-2_12openalex-snapshot
Ancillary Studies in the Cytologic Diagnosis of Pancreatico-biliary Lesions
inferred← citeshttps://doi.org/10.1007/978-3-030-30192-7_81openalex-snapshot
Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-37482-2_37-1openalex-snapshot
Pathology of Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-37482-2_39-1openalex-snapshot
Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs)
inferred← citeshttps://doi.org/10.1007/978-3-030-37482-2_40-1openalex-snapshot
Surgical Management of Pancreatic Neuroendocrine Tumors (PNET)
inferred← citeshttps://doi.org/10.1007/978-3-030-37482-2_43-1openalex-snapshot
Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-030-37482-2_50-1openalex-snapshot
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-38261-2_25openalex-snapshot
Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours
inferred← citeshttps://doi.org/10.1007/978-3-030-39457-8_32openalex-snapshot
Peptide Receptor Radionuclide Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-41683-6_37openalex-snapshot
Pathology of Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-41683-6_39openalex-snapshot
Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs)
inferred← citeshttps://doi.org/10.1007/978-3-030-41683-6_40openalex-snapshot
Surgical Management of Pancreatic Neuroendocrine Tumors (PNET)
inferred← citeshttps://doi.org/10.1007/978-3-030-41683-6_43openalex-snapshot
Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-030-41683-6_50openalex-snapshot
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-48363-0_18openalex-snapshot
Neuroendocrine Tumors (Gastroenteropancreatic)
inferred← citeshttps://doi.org/10.1007/978-3-030-48767-6_10openalex-snapshot
Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-030-51192-0_90-1openalex-snapshot
Radiopharmaceuticals and Systemic Therapies for Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-54391-4_19openalex-snapshot
The Management of Neuro-Endocrine Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_60openalex-snapshot
Neuroendocrine Neoplasms (NENs)
inferred← citeshttps://doi.org/10.1007/978-3-030-62241-1_18openalex-snapshot
Neuroendocrine Peritoneal Metastases
inferred← citeshttps://doi.org/10.1007/978-3-030-62241-1_20openalex-snapshot
Emerging Systemic Therapies for Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-67823-4_10-1openalex-snapshot
Navigating Hormone-Related Challenges: “Advances in Managing Functional Pancreatic Neuroendocrine Neoplasms”
inferred← citeshttps://doi.org/10.1007/978-3-030-67823-4_14-1openalex-snapshot
Systemic Therapy for Metastatic Disease: GEP NENs
inferred← citeshttps://doi.org/10.1007/978-3-030-67823-4_18-1openalex-snapshot
Future Trends in NEN Care: QoL and Multidisciplinary Care
inferred← citeshttps://doi.org/10.1007/978-3-030-67823-4_8-1openalex-snapshot
Role of Functional Imaging in NENs
inferred← citeshttps://doi.org/10.1007/978-3-030-70773-6_3openalex-snapshot
Gastro-entero-pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-70773-6_7openalex-snapshot
Intra-arterial Radiopeptide Infusions with High Activity of 111In-Octreotide: From “Aretaieion Protocol” to the Temporal Intra-arterial Port Installation
inferred← citeshttps://doi.org/10.1007/978-3-030-72830-4_14openalex-snapshot
Treatment of Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-72830-4_16openalex-snapshot
Treatment of NETs from Rare Origin
inferred← citeshttps://doi.org/10.1007/978-3-030-72830-4_4openalex-snapshot
Molecular Biology of Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-72830-4_9openalex-snapshot
New Approaches in Medical Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-97220-2_14openalex-snapshot
Systemic Treatments and Related Side Effects in Liver Tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-97220-2_8openalex-snapshot
Systemic Treatments and Related Side Effects in Thyroid Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-97220-2_9openalex-snapshot
Radionuclide Therapy in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-10839-6_5openalex-snapshot
Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-11363-5_8openalex-snapshot
Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents
inferred← citeshttps://doi.org/10.1007/978-3-031-16258-9_2openalex-snapshot
Growth Hormone-Releasing Hormone-Secreting Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-21351-9_4openalex-snapshot
Pancreatic Neuroendocrine Tumors: Diagnosis, Management, and Intraoperative Techniques
inferred← citeshttps://doi.org/10.1007/978-3-031-28524-0_19openalex-snapshot
Neuroendocrine Neoplasm Imaging and Image-Guided Therapies
inferred← citeshttps://doi.org/10.1007/978-3-031-49762-9_90openalex-snapshot
Radiopharmaceuticals and Systemic Therapies for Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-53858-2_11openalex-snapshot
Surgical Management of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-53858-2_12openalex-snapshot
Evidence-Based Guidelines for the Screening, Surveillance, and Management of VHL Manifestations
inferred← citeshttps://doi.org/10.1007/978-3-031-56968-5_1openalex-snapshot
Introduction to Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-56968-5_18openalex-snapshot
Non-Functioning Pancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-56968-5_21openalex-snapshot
The Multiple Endocrine Neoplasia Syndromes
inferred← citeshttps://doi.org/10.1007/978-3-031-56968-5_31openalex-snapshot
The Role of Chemotherapy in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-031-78409-5_17openalex-snapshot
Pancreatic Neuroendocrine Neoplasms
showing the first 200 of 2508 · page through all 2508
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.